Keep up-to-date with the latest access to medicines news and research, plus interviews and opinion from our partners and other experts, and videos and photo stories of our work.
News
-
AIDS 2020 leadership workshop: Strategies for lowering drug prices
Activists, policy-makers, researchers and healthcare providers joined a leadership workshop led by ITPC’s Make Medicines Affordable campaign at AIDS 2020...
-
COVID-19: Another of Gilead’s FIVE patent applications on remdesivir is opposed in Argentina
Our campaign partner, Fundación GEP, has filed a second patent opposition against one of Gilead’s numerous patent applications for the...
-
AIDS 2020 exhibition: Love, life and riots
We’re exhibiting at #AIDS2020Virtual, the world’s largest virtual AIDS conference. Our photo exhibition Love, Life and Riots will be on...
-
What’s on: AIDS 2020 Virtual for treatment activists
Kicking off on Monday 6 July, with a workshop on innovative strategies to reduce prohibitive drug prices, we’ve compiled some...
-
Ukraine: 100% LIFE opposes patent on TB drug for children
Our campaign partner in Ukraine, 100% LIFE, has submitted the first patent opposition on bedaquiline in the Eastern Europe and Central...
-
“Women must be able to decide what they want – for themselves”
Yupa, 46, from Lamphun, Thailand, is advocating for women to have more choices and control over their own sexual and...
-
Argentina: Fundación GEP opposes Gilead’s patent application on remdesivir
Our partner, Fundación GEP, has filed a patent opposition against Gilead’s patent application on remdesivir before the Argentinean Patent Office....
-
COVID-19: Local manufacturing essential if we are to “treat all”
ITPC led a virtual roundtable last week (26 May 2020) attended by civil society treatment experts, researchers, and national pharmaceutical...
-
Jeed: HIV treatment was like winning the lottery
Interviewed by Gemma Taylor. “I was diagnosed with HIV at 21, in 1995. Treatment wasn’t available in Thailand at the...
-
“Children are suffering side-effects from sub-standard HIV treatment”
The longer that HIV antiretroviral drugs (ARVs) have been around, the more that is being discovered about long-term side-effects. In...
-
Moroccan civil society calls for compulsory licence on Gilead’s possible COVID-19 drug
On 12 May 2020, Gilead Sciences announced voluntary licenses to five generic manufacturers in India and Pakistan allowing them to...
-
Brazil and Thailand: Activists oppose more TB patents during COVID-19 pandemic
Bedaquiline (BDQ) is a core component of an ‘all-oral’ solution to multi-drug resistant TB (MDR-TB), and is recommended by the...